SI2601949T1 - Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina - Google Patents

Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina

Info

Publication number
SI2601949T1
SI2601949T1 SI201030784T SI201030784T SI2601949T1 SI 2601949 T1 SI2601949 T1 SI 2601949T1 SI 201030784 T SI201030784 T SI 201030784T SI 201030784 T SI201030784 T SI 201030784T SI 2601949 T1 SI2601949 T1 SI 2601949T1
Authority
SI
Slovenia
Prior art keywords
methylphenylć
ethoxybenzyl
glucitol
anhydro
thio
Prior art date
Application number
SI201030784T
Other languages
English (en)
Slovenian (sl)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of SI2601949T1 publication Critical patent/SI2601949T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201030784T 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina SI2601949T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
EP13157571.4A EP2601949B1 (en) 2009-04-16 2010-04-16 Pharmaceutical compositions with (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol and an insulin secretagogue.

Publications (1)

Publication Number Publication Date
SI2601949T1 true SI2601949T1 (sl) 2014-12-31

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201030365T SI2419097T1 (sl) 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in metformin in njegove uporabe pri zdravljenju diabetesa
SI201030784T SI2601949T1 (sl) 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201030365T SI2419097T1 (sl) 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in metformin in njegove uporabe pri zdravljenju diabetesa

Country Status (30)

Country Link
US (1) US20120040898A1 (enExample)
EP (3) EP2829271A3 (enExample)
JP (4) JP5077786B2 (enExample)
KR (2) KR20120016051A (enExample)
CN (7) CN105343059A (enExample)
AR (1) AR076317A1 (enExample)
AU (1) AU2010237748B2 (enExample)
BR (1) BRPI1012539A2 (enExample)
CA (1) CA2755392A1 (enExample)
CY (2) CY1114703T1 (enExample)
DK (2) DK2419097T3 (enExample)
ES (2) ES2523408T3 (enExample)
HK (6) HK1217302A1 (enExample)
HR (2) HRP20131120T1 (enExample)
ME (2) ME01555B (enExample)
MX (1) MX2011010901A (enExample)
MY (3) MY182720A (enExample)
NZ (4) NZ606888A (enExample)
PH (3) PH12015500235B1 (enExample)
PL (2) PL2419097T3 (enExample)
PT (2) PT2601949E (enExample)
RS (2) RS53761B1 (enExample)
RU (2) RU2532330C2 (enExample)
SG (6) SG175154A1 (enExample)
SI (2) SI2419097T1 (enExample)
SM (1) SMT201500015B (enExample)
TW (3) TW201622720A (enExample)
UA (2) UA105216C2 (enExample)
WO (1) WO2010119990A1 (enExample)
ZA (1) ZA201106727B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DK2486029T3 (en) 2009-09-30 2015-08-24 Boehringer Ingelheim Int Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1202458A1 (en) 2012-05-17 2015-10-02 Vtv治疗有限责任公司 Glucokinase activator compositions for the treatment of diabetes
TW201414472A (zh) 2012-08-30 2014-04-16 大正製藥股份有限公司 Ｓｇｌｔ２抑制藥與抗高血壓藥之組合
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
AU2015384339B2 (en) * 2015-02-27 2018-08-09 The Asan Foundation Composition for preventing or treating valve calcification, containing DPP-4 inhibitor
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
MX2019004549A (es) 2016-10-19 2019-06-12 Boehringer Ingelheim Int Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
AU2017357589B2 (en) 2016-11-10 2023-05-11 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN110168098A (zh) * 2016-11-14 2019-08-23 高雄医学大学 一种检测糖代谢异常的方法及其预防及治疗
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
CN112955214B (zh) 2018-10-29 2024-05-07 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
BR112021004635A2 (pt) 2018-10-29 2021-05-25 Boehringer Ingelheim International Gmbh derivados de piridinil sulfonamida, composições farmacêuticas e usos das mesmas
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
JP4590159B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
ES2258141T3 (es) * 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
BRPI0713058A2 (pt) * 2006-06-29 2012-04-10 Taisho Pharmaceutical Co., Ltd. composto de 1-tioglucitol de c-fenila
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
JP5384343B2 (ja) * 2006-08-15 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
CA2669043A1 (en) * 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
JPWO2008072726A1 (ja) * 2006-12-14 2010-04-02 大正製薬株式会社 １−フェニル １−チオ−ｄ−グルシト−ル誘導体
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.

Also Published As

Publication number Publication date
CY1115907T1 (el) 2017-01-25
HK1217434A1 (zh) 2017-01-13
ME01555B (me) 2014-04-20
SG2014012462A (en) 2014-05-29
JP2013006854A (ja) 2013-01-10
PL2601949T3 (pl) 2015-04-30
PH12019500959A1 (en) 2020-06-29
CY1114703T1 (el) 2016-10-05
PH12019500961B1 (en) 2020-08-03
ES2431300T3 (es) 2013-11-25
RU2532330C2 (ru) 2014-11-10
HK1217435A1 (zh) 2017-01-13
TW201622720A (zh) 2016-07-01
EP2419097B1 (en) 2013-09-25
JP5077786B2 (ja) 2012-11-21
SG2014015093A (en) 2014-04-28
HRP20131120T1 (hr) 2013-12-20
UA111742C2 (uk) 2016-06-10
HK1217302A1 (zh) 2017-01-06
JP5660094B2 (ja) 2015-01-28
RU2014121260A (ru) 2015-12-10
JP2015063543A (ja) 2015-04-09
DK2419097T3 (da) 2013-10-28
ES2523408T3 (es) 2014-11-25
TW201500043A (zh) 2015-01-01
EP2419097A1 (en) 2012-02-22
RU2011146335A (ru) 2013-05-27
SG2014014807A (en) 2014-05-29
CN105343871A (zh) 2016-02-24
PH12019500959B1 (en) 2020-06-29
HK1218871A1 (zh) 2017-03-17
SG2014012405A (en) 2014-05-29
PH12019500961A1 (en) 2020-08-03
JP6066144B2 (ja) 2017-01-25
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
RS53761B1 (sr) 2015-06-30
ZA201106727B (en) 2012-11-28
TW201103534A (en) 2011-02-01
PH12015500235A1 (en) 2015-12-02
AR076317A1 (es) 2011-06-01
KR20150046382A (ko) 2015-04-29
NZ623838A (en) 2015-09-25
NZ606888A (en) 2014-07-25
AU2010237748B2 (en) 2014-10-30
CN105343060A (zh) 2016-02-24
PL2419097T3 (pl) 2014-02-28
US20120040898A1 (en) 2012-02-16
CN105343880A (zh) 2016-02-24
CN105477639A (zh) 2016-04-13
CA2755392A1 (en) 2010-10-21
UA105216C2 (en) 2014-04-25
EP2601949A2 (en) 2013-06-12
PT2601949E (pt) 2014-11-12
MY182720A (en) 2021-02-03
JP2016104775A (ja) 2016-06-09
HK1218881A1 (zh) 2017-03-17
DK2601949T3 (da) 2015-01-05
CN102395364A (zh) 2012-03-28
EP2601949A3 (en) 2013-09-18
BRPI1012539A2 (pt) 2016-03-29
NZ595314A (en) 2013-03-28
EP2419097A4 (en) 2012-09-05
MX2011010901A (es) 2011-11-01
ME02015B (me) 2015-05-20
CN105434430A (zh) 2016-03-30
PT2419097E (pt) 2013-10-03
MY156679A (en) 2016-03-15
EP2829271A3 (en) 2015-05-27
AU2010237748A1 (en) 2011-10-20
RS53056B (sr) 2014-04-30
PH12015500235B1 (en) 2015-12-02
SMT201500015B (it) 2015-03-05
SG175154A1 (en) 2011-11-28
CN105343059A (zh) 2016-02-24
JP5910711B2 (ja) 2016-04-27
WO2010119990A1 (en) 2010-10-21
EP2601949B1 (en) 2014-10-29
NZ710575A (en) 2016-06-24
HK1217301A1 (zh) 2017-01-06
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
JP2012524710A (ja) 2012-10-18
SG2014012553A (en) 2014-05-29
MY183793A (en) 2021-03-16

Similar Documents

Publication Publication Date Title
SI2601949T1 (sl) Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina
HUS2400029I1 (hu) Proteáz-stabilizált, acilált inzulin-analógok
PT3417871T (pt) Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
EP2499195A4 (en) Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
IL220509A (en) Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination
IL216254A (en) Compounds, pharmaceutical compositions and their uses
BRPI1010768A2 (pt) composto, e, composição farmacêutica.
IL220284A0 (en) Insulin analogues with chlorinated amino acids, compositions comprising the same and uses thereof
EP2455123A4 (en) Piston for syringe having very small capacity, and plunger having the piston mounted thereto
IL213997A0 (en) Heteroatom- containing cyclic compounds, compositions comprising the same and uses thereof
PL2579928T3 (pl) Zespół napędowy, komponent napędu i urządzenie do podawania leku
IL222137A (en) Extensive use protection device, intended in particular for syringes and the like
AP2011005697A0 (en) The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof.
AP2011006033A0 (en) Simalikalactone E and use thereof as a medicament.
申大利 et al. 没确桑昂地区铅铜多金属矿物化探异常特征及找矿前景
张芬英 et al. 都兰县洪水河铁矿地质特征及成因分析
蒋涵毅 CAVDY
Yang Suggestion on Green Food Labeling
刘江峰 青海省扎麻什西沟金铜矿床地质特征及成矿条件浅析
刘钦 et al. 冷冻法在三山岛新立矿区的工程实践
郭广军 et al. SURPAC 软件在焦家金矿自动化制图中的应用
张凯 et al. 变频器运行中谐波的危害及治理方法
Zhao JUAN ER, FANG CAO BU
张奇 et al. 静态留矿法设计与施工技术问题探讨
曾凡龙 et al. 黑龙江桦南三道沟金矿地质特征及找矿标志